Yingzi Cui
Changchun University
17 Papers
2 Citations
Yingzi Cui is an academic researcher from Changchun University. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Analysis of influencing factors on long COVID in COVID-19 patients infected with omicron variant three months after discharge: a cross-sectional study
Hang Shang,Tianying Chang,Wei Yang,Li Shi,Shaodan Hu,Lin Tian,Jixiang Ren,Tan Wang,Jian Wang,Jiajuan Guo,Yingzi Cui +10 more
TL;DR: The most common symptoms of Long COVID were persistent fatigue, amnesia, insomnia and excessive sweating, and female patients were at a higher risk of Long COVID.
3
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial
Zhongnan Xu,Zhengzhi Liu,Yanli Wang,Jinling Xue,Tianying Chang,Yingzi Cui,Yang Cheng,Guang-ping Liu,Wan-lu Wang,Yan-Nan Zhou,Shuang Yu,Qing Ren,Wei Yang,Xin-Ning Qu,Jiahui Chen,Xue-si Chen,Qiaohuan Deng,Haimiao Yang,Xiuge Wang +18 more
TL;DR: Wang et al. as discussed by the authors investigated the bioequivalence and safety of the test and reference drugs in healthy Chinese subjects, where subjects were randomly divided into group A and group B at a ratio of 1:1 for a two-cycle cross-over study.
2
Reporting Quality of Oral TCM Systematic Reviews Based on the PRISMA Harms Checklist from 2013 to 2020
TL;DR: This paper used the PRISMA harms checklist to assess the quality of reporting of the safety information of oral traditional Chinese medicine (TCM) in systematic reviews and explored factors associated with better reporting.
Exploring the Potential Mechanism of Qi-Shen-Di-Huang Drug Formulary for Myasthenia Gravis (MG) based on UHPLC-QE-MS Network Pharmacology and Molecular Docking Techniques
Yibin Zhang,Tianying Chang,Qi Lu,Yingzi Cui,Dongmei Zhang,Baitong Wang,Peng Xu,Jing Luo,Jinhui Ma,Zhiguo Lv,Jian Wang +10 more
TL;DR: The role and potential mechanism of the QSDH drug formulary in the treatment of MG is described, which exerts potential value by acting on AKT targets and regulating the PI3K/AKT signaling pathway and providing a theoretical reference for Q SDH drugformulary application in the clinical treatment ofMG.
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects
Yanli Wang,Jinling Xue,Zhengjie Su,Yingzi Cui,Guang-ping Liu,Wei Yang,Zhengzhi Liu,Jiahui Chen,Qing Ren,Shuang Yu,Yang Cheng,Yan-Nan Zhou,Wan-lu Wang,Xue-si Chen,Dongmei Qu,Qiaohuan Deng,Yicheng Zhao,Haimiao Yang +17 more
TL;DR: In this article , the authors designed a clinical study to demonstrate that Dasatinib tablet (YiNiShu®) (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) were bioequivalent under fasting and fed conditions.
1